234 related articles for article (PubMed ID: 24202242)
1. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States.
Narayanan S; Wilson K; Ogelsby A; Juneau P; Durden E
J Occup Environ Med; 2013 Nov; 55(11):1262-70. PubMed ID: 24202242
[TBL] [Abstract][Full Text] [Related]
2. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis.
Carls G; Li T; Panopalis P; Wang S; Mell AG; Gibson TB; Goetzel RZ
J Occup Environ Med; 2009 Jan; 51(1):66-79. PubMed ID: 19136875
[TBL] [Abstract][Full Text] [Related]
3. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O
Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074
[TBL] [Abstract][Full Text] [Related]
4. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
5. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
[TBL] [Abstract][Full Text] [Related]
6. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
[TBL] [Abstract][Full Text] [Related]
7. Costs associated with severe and nonsevere systemic lupus erythematosus in Canada.
Clarke AE; Urowitz MB; Monga N; Hanly JG
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):431-6. PubMed ID: 25185936
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
Clarke AE; Yazdany J; Kabadi SM; Durden E; Winer I; Griffing K; Costenbader KH
Semin Arthritis Rheum; 2020 Aug; 50(4):759-768. PubMed ID: 32531505
[TBL] [Abstract][Full Text] [Related]
9. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
Kariburyo F; Xie L; Sah J; Li N; Lofland JH
J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
[No Abstract] [Full Text] [Related]
10. The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.
Khamashta MA; Bruce IN; Gordon C; Isenberg DA; Ateka-Barrutia O; Gayed M; Donatti C; Guillermin AL; Foo J; Perna A
Lupus; 2014 Mar; 23(3):273-83. PubMed ID: 24356612
[TBL] [Abstract][Full Text] [Related]
11. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease.
Karve S; Candrilli S; Kappelman MD; Tolleson-Rinehart S; Tennis P; Andrews E
J Pediatr; 2012 Oct; 161(4):662-670.e2. PubMed ID: 22578787
[TBL] [Abstract][Full Text] [Related]
12. The impact of flare on disease costs of patients with systemic lupus erythematosus.
Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597
[TBL] [Abstract][Full Text] [Related]
13. Annual direct medical cost of active systemic lupus erythematosus in five European countries.
Doria A; Amoura Z; Cervera R; Khamastha MA; Schneider M; Richter J; Guillemin F; Kobelt G; Maurel F; Garofano A; Perna A; Murray M; Schmitt C; Boucot I
Ann Rheum Dis; 2014 Jan; 73(1):154-60. PubMed ID: 23264339
[TBL] [Abstract][Full Text] [Related]
14. Cost-of-illness studies in systemic lupus erythematosus: A systematic review.
Zhu TY; Tam LS; Li EK
Arthritis Care Res (Hoboken); 2011 May; 63(5):751-60. PubMed ID: 21557530
[TBL] [Abstract][Full Text] [Related]
15. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population.
Furst DE; Clarke A; Fernandes AW; Bancroft T; Gajria K; Greth W; Iorga SR
Lupus; 2013 Mar; 22(3):268-78. PubMed ID: 23340996
[TBL] [Abstract][Full Text] [Related]
16. The direct and indirect cost burden of Crohn's disease and ulcerative colitis.
Gibson TB; Ng E; Ozminkowski RJ; Wang S; Burton WN; Goetzel RZ; Maclean R
J Occup Environ Med; 2008 Nov; 50(11):1261-72. PubMed ID: 19001952
[TBL] [Abstract][Full Text] [Related]
17. Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: the LUCIE Study.
Cervera R; Rúa-Figueroa I; Gil-Aguado A; Sabio JM; Pallarés L; Hernández-Pastor LJ; Iglesias M
Rev Clin Esp (Barc); 2013 Apr; 213(3):127-37. PubMed ID: 23398815
[TBL] [Abstract][Full Text] [Related]
18. Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States.
Drenkard C; Bao G; Dennis G; Kan HJ; Jhingran PM; Molta CT; Lim SS
Arthritis Care Res (Hoboken); 2014 Jun; 66(6):878-87. PubMed ID: 24339382
[TBL] [Abstract][Full Text] [Related]
19. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
20. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
